Adarigiline (INN) is a monoamine oxidase inhibitor (MAOI) that was never marketed. It is specifically a monoamine oxidase B (MAO-B) inhibitor. This drug candidate was first described in 2009, in a patent assigned to Helicon Therapeutics.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.